Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278156 | 0.88 | ADORA2A (0.54) | ADORA2AADORA1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL4293192 | 0.85 | ADORA2A (0.65) | ADORA2AADORA1 | |
| SCHEMBL1450021 | 0.83 | ALDH1A1 (0.51) | ADORA2AADORA1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL4283731 | 0.83 | ADORA2A (0.47) | ADORA2AADORA1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL1449595 | 0.78 | ADORA2A (0.63) | ADORA2AADORA1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1450249 | 0.75 | ADORA2A (0.63) | ADORA2AADORA1 | |
| SCHEMBL12127937 | 0.74 | ALDH1A1 (0.56) | RAB9ACYP1A2CYP2C9CYP2C19NPC1 | |
| SCHEMBL15484655 | 0.72 | ADORA2A (0.55) | ADORA2AADORA1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1450089 | 0.72 | ADORA2A (0.67) | ADORA2AADORA1RAB9AMEN1KMT2A | |
| SCHEMBL1449788 | 0.70 | ADORA2A (0.85) | ADORA2AADORA1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | claimed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | claimed |
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | ADORA2A 1/4885ADORA1 7/4885RAB9A 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.